Total Payments
$1,481
2023 Payments
$164.14
Companies
16
Transactions
38
Medicare Patients
2,381
Medicare Billing
$132,032
Payment Breakdown by Category
Food & Beverage$1,481 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,481 | 38 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $383.86 | 3 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $249.89 | 5 | $0 (2023) |
| Roche Diagnostics Corporation | $155.24 | 3 | $0 (2023) |
| Merck Sharp & Dohme LLC | $141.48 | 3 | $0 (2022) |
| Myriad Genetic Laboratories, Inc. | $124.59 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $122.92 | 6 | $0 (2019) |
| Amgen Inc. | $78.95 | 5 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $58.59 | 3 | $0 (2019) |
| Celgene Corporation | $46.91 | 2 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.28 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $164.14 | 2 | Roche Diagnostics Corporation ($87.46) |
| 2022 | $375.96 | 3 | Genentech USA, Inc. ($144.30) |
| 2021 | $123.44 | 1 | AstraZeneca Pharmaceuticals LP ($123.44) |
| 2019 | $410.72 | 16 | Genentech USA, Inc. ($116.47) |
| 2018 | $174.80 | 10 | Amgen Inc. ($49.71) |
| 2017 | $231.54 | 6 | Genentech USA, Inc. ($123.09) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/18/2023 | Roche Diagnostics Corporation | — | Food and Beverage | In-kind items and services | $87.46 | General |
| Category: None | ||||||
| 02/17/2023 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $76.68 | General |
| Category: Oncology | ||||||
| 09/22/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $144.30 | General |
| 09/14/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $107.07 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2022 | Myriad Genetic Laboratories, Inc. | myRisk (Device) | Food and Beverage | Cash or cash equivalent | $124.59 | General |
| Category: Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | ||||||
| 09/09/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $123.44 | General |
| Category: Oncology | ||||||
| 11/12/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2019 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $116.47 | General |
| 09/23/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2019 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2019 | Amgen Inc. | MVASI (Biological), Neulasta, Vectibix | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Oncology | ||||||
| 08/29/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $23.28 | General |
| 08/20/2019 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | Food and Beverage | In-kind items and services | $15.64 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2019 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2019 | Roche Diagnostics Corporation | TD BenchMark IHC/ISH and Special Stains Reagents (Device) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: Tissue Diagnostics | ||||||
| 05/30/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/04/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.98 | General |
| Category: Oncology | ||||||
| 02/27/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.38 | General |
| Category: Oncology | ||||||
| 01/24/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.69 | General |
| Category: Oncology | ||||||
| 01/08/2019 | Helsinn Therapeutics (U.S.), Inc. | AKYNZEO (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| 12/18/2018 | Amgen Inc. | Aranesp (Biological), Nplate, Prolia | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Nephrology | ||||||
| 10/30/2018 | Amgen Inc. | Neulasta (Biological) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Oncology | ||||||
| 09/11/2018 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 666 | 1,166 | $367,328 | $33,604 |
| 2022 | 12 | 704 | 1,219 | $411,351 | $40,105 |
| 2021 | 9 | 600 | 1,085 | $358,984 | $35,448 |
| 2020 | 9 | 411 | 693 | $221,883 | $22,875 |
Total Patients
2,381
Total Services
4,163
Medicare Billing
$132,032
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 264 | 627 | $202,521 | $17,789 | 8.8% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2023 | 31 | 49 | $28,077 | $3,259 | 11.6% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2023 | 28 | 46 | $17,158 | $2,286 | 13.3% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2023 | 14 | 17 | $11,577 | $1,966 | 17.0% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 29 | 86 | $29,670 | $1,949 | 6.6% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 64 | 70 | $24,150 | $1,822 | 7.5% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Office | 2023 | 18 | 19 | $4,389 | $1,546 | 35.2% |
| 88112 | Cell examination of specimen, selective cellular enhancement technique | Facility | 2023 | 34 | 38 | $12,502 | $817.73 | 6.5% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2023 | 58 | 73 | $15,768 | $684.12 | 4.3% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2023 | 36 | 45 | $4,230 | $458.11 | 10.8% |
| 88112 | Cell examination of specimen, selective cellular enhancement technique | Office | 2023 | 17 | 18 | $5,490 | $397.81 | 7.2% |
| 88363 | Examination of archival tissue for genetic analysis | Facility | 2023 | 23 | 24 | $5,424 | $391.44 | 7.2% |
| 88300 | Pathology examination of tissue using a microscope, limited examination | Facility | 2023 | 35 | 39 | $4,212 | $150.09 | 3.6% |
| 88302 | Pathology examination of tissue using a microscope | Facility | 2023 | 15 | 15 | $2,160 | $87.75 | 4.1% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 303 | 665 | $214,795 | $20,083 | 9.3% |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | Office | 2022 | 11 | 11 | $14,608 | $3,262 | 22.3% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 33 | 47 | $26,931 | $3,191 | 11.8% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 93 | 101 | $34,845 | $2,865 | 8.2% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2022 | 33 | 116 | $40,020 | $2,686 | 6.7% |
| 88112 | Cell examination of specimen, selective cellular enhancement technique | Facility | 2022 | 58 | 76 | $25,004 | $1,725 | 6.9% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2022 | 22 | 30 | $11,190 | $1,528 | 13.7% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Office | 2022 | 17 | 18 | $4,158 | $1,506 | 36.2% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2022 | 12 | 12 | $8,172 | $1,317 | 16.1% |
| 88112 | Cell examination of specimen, selective cellular enhancement technique | Office | 2022 | 39 | 46 | $14,030 | $1,045 | 7.4% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2022 | 37 | 43 | $9,288 | $415.56 | 4.5% |
About Dr. Monica Recine, MD
Dr. Monica Recine, MD is a Anatomic Pathology healthcare provider based in Miami Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407886757.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Monica Recine, MD has received a total of $1,481 in payments from pharmaceutical and medical device companies, with $164.14 received in 2023. These payments were reported across 38 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($1,481).
As a Medicare-enrolled provider, Recine has provided services to 2,381 Medicare beneficiaries, totaling 4,163 services with total Medicare billing of $132,032. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Anatomic Pathology
- Other Specialties Anatomic Pathology & Clinical Pathology, Clinical Pathology/Laboratory Medicine
- Location Miami Beach, FL
- Active Since 07/03/2006
- Last Updated 09/18/2007
- Taxonomy Code 207ZP0101X
- Entity Type Individual
- NPI Number 1407886757
Products in Payments
- KEYTRUDA (Biological) $125.72
- myRisk (Device) $124.59
- IMFINZI (Biological) $123.44
- ENHERTU (Biological) $76.68
- MEKINIST (Drug) $69.70
- TD BenchMark IHC/ISH and Special Stains Reagents (Device) $67.78
- OPDIVO (Biological) $58.59
- TAGRISSO (Drug) $49.77
- Abraxane (Drug) $46.91
- Neulasta (Biological) $45.97
- VOTRIENT (Drug) $37.58
- FOUNDATIONONE (Device) $22.46
- GILOTRIF (Drug) $17.45
- Aranesp (Biological) $16.89
- MVASI (Biological) $16.09
- ZERBAXA (Drug) $15.76
- PIQRAY (Drug) $15.64
- IDHIFA (Drug) $13.75
- AKYNZEO (Drug) $13.49
- Xermelo (Drug) $12.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.